181 related articles for article (PubMed ID: 8213217)
1. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Moritaka T; Shibayama T; Tabata M; Segawa Y; Takigawa N
Acta Med Okayama; 1993 Aug; 47(4):233-41. PubMed ID: 8213217
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
3. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
Kiura K; Ohnoshi T; Ueoka H; Takigawa N; Tabata M; Segawa Y; Shibayama T; Kimura I
Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin.
Kobayashi H; Takemura Y; Miyachi H; Ogawa T
Invest New Drugs; 1991 Nov; 9(4):313-9. PubMed ID: 1804804
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
Takigawa N; Ohnoshi T; Ueoka H; Horiguchi T; Kiura K; Tabata M; Segawa Y; Shibayama T; Genba K; Matsumura T
Gan To Kagaku Ryoho; 1993 Jul; 20(9):1221-6. PubMed ID: 8392827
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
8. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
Acta Med Okayama; 1992 Aug; 46(4):249-56. PubMed ID: 1442149
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
[TBL] [Abstract][Full Text] [Related]
13. Tumoricidal interactions of hyperthermia with carboplatin, cisplatin and etoposide.
Cohen JD; Robins HI; Schmitt CL
Cancer Lett; 1989 Mar; 44(3):205-10. PubMed ID: 2647285
[TBL] [Abstract][Full Text] [Related]
14. In vitro chemosensitivity and radiosensitivity of an adriamycin-resistant subline of human small cell lung cancer cells.
Miyamoto H
Acta Med Okayama; 1986 Apr; 40(2):75-81. PubMed ID: 3012966
[TBL] [Abstract][Full Text] [Related]
15. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the antitumor activity of newly developed platinum analogs in lung cancer using the colony assay].
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Yamashita H; Kozuka A; Moritaka T; Uji H; Kiura K; Mima Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):427-30. PubMed ID: 2539056
[No Abstract] [Full Text] [Related]
17. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
[TBL] [Abstract][Full Text] [Related]
18. [Effects of cisplatin, carboplatin, etoposide and human hepatocyte growth factor on the colony formation of four human liver cancer cell lines].
Seshimo K; Hamasaki K; Gohda E; Orita K; Namba M
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1967-72. PubMed ID: 8215470
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analyses of the characteristics of tumor cells treated with two platinum compounds: 1,1-cyclobutanedicarboxylato(2-aminomethylpyrrolidine)- platinum(II) and cisplatin.
Inoue S; Mizuno S; Ito M; Ohnuma T
Jpn J Cancer Res; 1992 Nov; 83(11):1231-40. PubMed ID: 1483936
[TBL] [Abstract][Full Text] [Related]
20. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]